Literature DB >> 15988065

Generation of PDE4 knockout mice by gene targeting.

S-L Catherine Jin1, Anne M Latour, Marco Conti.   

Abstract

The development of gene-targeting techniques has ushered in a new era in mouse genetics. Two discoveries have been instrumental: the finding that an exogenous DNA introduced in mammalian cells can recombine with homologous chromosomal sequences, a process known as gene targeting, and the revelation that cultured embryonic stem (ES) cells when injected into early stage mouse embryos can contribute to produce germ-line chimeras. On the basis of these seminal findings, gene targeting by homologous recombination in mouse ES cells in vitro has been established as a powerful means of altering specific loci in the mouse genome. As a result, gene function can be studied in vivo. By applying this technology, targeted disruption of PDE4 alleles is created in cultured ES cells and, subsequently, the mutant ES cells are injected into blastocysts and returned to pseudopregnant foster mothers to produce germ-line chimeric pups. In this chapter, we describe the basic protocols used to generate the PDE4 knockout mice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15988065     DOI: 10.1385/1-59259-839-0:191

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

1.  Phosphodiesterase 4B in the cardiac L-type Ca²⁺ channel complex regulates Ca²⁺ current and protects against ventricular arrhythmias in mice.

Authors:  Jérôme Leroy; Wito Richter; Delphine Mika; Liliana R V Castro; Aniella Abi-Gerges; Moses Xie; Colleen Scheitrum; Florence Lefebvre; Julia Schittl; Philippe Mateo; Ruth Westenbroek; William A Catterall; Flavien Charpentier; Marco Conti; Rodolphe Fischmeister; Grégoire Vandecasteele
Journal:  J Clin Invest       Date:  2011-06-13       Impact factor: 14.808

Review 2.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

3.  Control of cytoplasmic and nuclear protein kinase A by phosphodiesterases and phosphatases in cardiac myocytes.

Authors:  Zeineb Haj Slimane; Ibrahim Bedioune; Patrick Lechêne; Audrey Varin; Florence Lefebvre; Philippe Mateo; Valérie Domergue-Dupont; Matthias Dewenter; Wito Richter; Marco Conti; Ali El-Armouche; Jin Zhang; Rodolphe Fischmeister; Grégoire Vandecasteele
Journal:  Cardiovasc Res       Date:  2014-02-18       Impact factor: 10.787

Review 4.  The role of phosphodiesterases in schizophrenia : therapeutic implications.

Authors:  Judith A Siuciak
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.

Authors:  Judith A Siuciak; Sheryl A McCarthy; Douglas S Chapin; Ashley N Martin
Journal:  Psychopharmacology (Berl)       Date:  2007-12-01       Impact factor: 4.530

6.  Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B).

Authors:  Han-Ting Zhang; Ying Huang; Anbrin Masood; Lisa R Stolinski; Yunfeng Li; Lei Zhang; Daniel Dlaboga; S-L Catherine Jin; Marco Conti; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2007-08-15       Impact factor: 7.853

7.  Heterologous desensitization of cardiac β-adrenergic signal via hormone-induced βAR/arrestin/PDE4 complexes.

Authors:  Qian Shi; Minghui Li; Delphine Mika; Qin Fu; Sungjin Kim; Jason Phan; Ao Shen; Gregoire Vandecasteele; Yang K Xiang
Journal:  Cardiovasc Res       Date:  2017-05-01       Impact factor: 10.787

8.  Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.

Authors:  Judith A Siuciak; Douglas S Chapin; Sheryl A McCarthy; Ashley N Martin
Journal:  Psychopharmacology (Berl)       Date:  2007-03-02       Impact factor: 4.415

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.